PACS, RIS, and CVIS – Market Insights – United States

The US PACS, RIS, and CVIS market is projected to experience modest expansion through 2033. This growth is driven by the increasing rates of chronic illnesses in the US that drive radiology and cardiology procedure volumes, as well as the continued efforts by manufacturers to integrate AI/ML that streamline clinical workflows, increase efficiency, and reduce costs. However, overall market expansion will be hindered by market saturation, which is driving increased price competition among vendors, as well as facility budget constraints for capital equipment, and an increasing shift toward enterprise solutions.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for PACS, RIS, and CVIS in the US from 2019 through 2033.

The US market for PACS, RIS, and CVIS is nearing saturation across many facility types.

What is the penetration of PACS, RIS, and CVIS in the US across different facility types?

Which types of facilities have already reached saturation, and which are still seeing incremental sales?

What is the expected volume of replacement sales through 2033?

Adoption of new emerging technologies as replacements for traditional PACS, RIS, and CVIS will rapidly change market prospects.

What are the emerging technologies that are affecting the future of the traditional PACS, RIS, and CVIS markets?

How will the adoption of enhanced diagnostic tools such as AI and machine learning change the market, and what are the competitive implications of this technology?

Strategic collaborations between traditional HCIT companies and tech companies are pivotal for staying competitive in the PACS, RIS, and CVIS market.

How will mergers and acquisitions change the competitive landscape of the PACS, RIS, and CVIS market?

How will AI integration affect the competitiveness of certain companies?

Despite the substantial market size of PACS, RIS, and CVIS in the US, growth of VNA and EHRs is expected to constrain this market.

How will widespread adoption of EHRs and VNAs affect the PACS, RIS, and CVIS market?

How can traditional PACS vendors position themselves in a market that increasingly prioritizes vendor neutrality and interoperability between IT solutions?

Hospital consolidation is driving demand for high-value PACS, RIS, and CVIS contracts.

How will hospital consolidation and declining physician influence affect purchasing decisions for PACS, RIS, and CVIS?

Which vendors will benefit the most from this changing landscape?

Cybersecurity in the HCIT sector is a growing topic of discussion, and vendors are increasingly investing in improving the security of their systems.

How has hospital consolidation affected cybersecurity needs in this space?

How and why are cybersecurity-related certifications being used by PACS, RIS, and CVIS competitors?

Table of contents

PACS, RIS, and CVIS - Market Insights - United States

Sumit Jain, MS Pharm

Sumit Jain is a senior team lead within the Endoscopy, Diagnostics, and Healthcare IT Medtech Insights team at Clarivate, focusing on diagnostic imaging capital equipment and healthcare IT markets. Sumit holds a Bachelor’s degree in Pharmacy from the Rajiv Gandhi Technical University, Bhopal, and a Master’s degree in Pharmacoinformatics from the National Institute of Pharmaceutical Education and Research, Mohali.

Contact sales Login to access report

Back to all Medtech Insights reports